International Journal of Cancer Management

Published by: Kowsar
Crossmark
Uncorrected Proof scheduled for 12 (6)

Association of Lung Cancer and Tuberculosis: A Cross Sectional Study from Northwest of Iran

Parviz Saleh 1 , Mohammad-Salar Hosseini 2 , Reza Piri 3 , 4 , Mehrnaz Ghaffari 5 , Sahar Mohammadi 6 and Mohammad Naghavi-Behzad ORCID 2 , 7 , *
Authors Information
1 Chronic Kidney Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
3 Medical Philosophy and History Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark
5 Infectious and Tropical Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
6 Department of Emergency Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
7 Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Article information
  • International Journal of Cancer Management: In Press (In Press); e89915
  • Published Online: June 1, 2019
  • Article Type: Research Article
  • Received: January 26, 2019
  • Revised: April 29, 2019
  • Accepted: May 13, 2019
  • DOI: 10.5812/ijcm.89915

To Cite: Saleh P, Hosseini M, Piri R, Ghaffari M, Mohammadi S, et al. Association of Lung Cancer and Tuberculosis: A Cross Sectional Study from Northwest of Iran, Int J Cancer Manag. Online ahead of Print ; In Press(In Press):e89915. doi: 10.5812/ijcm.89915.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Bhatt M, Kant S, Bhaskar R. Pulmonary tuberculosis as differential diagnosis of lung cancer. South Asian J Cancer. 2012;1(1):36-42. doi: 10.4103/2278-330X.96507. [PubMed: 24455507]. [PubMed Central: PMC3876596].
  • 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi: 10.3322/caac.21442. [PubMed: 29313949].
  • 3. Yu YH, Liao CC, Hsu WH, Chen HJ, Liao WC, Muo CH, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: A population cohort study. J Thorac Oncol. 2011;6(1):32-7. doi: 10.1097/JTO.0b013e3181fb4fcc. [PubMed: 21150470].
  • 4. Williams MD, Sandler AB. The epidemiology of lung cancer. Cancer Treat Res. 2001;105:31-52. [PubMed: 11224993].
  • 5. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271-89. doi: 10.3322/caac.21349. [PubMed: 27253694].
  • 6. Liang HY, Li XL, Yu XS, Guan P, Yin ZH, He QC, et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: A systematic review. Int J Cancer. 2009;125(12):2936-44. doi: 10.1002/ijc.24636. [PubMed: 19521963].
  • 7. Haghdoost AA, Afshari M, Baneshi MR, Gouya MM, Nasehi M, Movahednia M. Estimating the annual risk of tuberculosis infection and disease in southeast of Iran using the bayesian mixture method. Iran Red Crescent Med J. 2014;16(9). e15308. doi: 10.5812/ircmj.15308. [PubMed: 25593722]. [PubMed Central: PMC4270654].
  • 8. Li X, Wang L, Tan Y, Hou J, Ma J. Distinct prevalence of drug-resistant tuberculosis in Gansu, China: A retrospective study on drug susceptibility profiles between 2010 and 2014. Microb Drug Resist. 2017;23(8):1025-31. doi: 10.1089/mdr.2016.0208. [PubMed: 28445109].
  • 9. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: The role of risk factors and social determinants. Soc Sci Med. 2009;68(12):2240-6. doi: 10.1016/j.socscimed.2009.03.041. [PubMed: 19394122].
  • 10. Archontogeorgis K, Steiropoulos P, Tzouvelekis A, Nena E, Bouros D. Lung cancer and interstitial lung diseases: A systematic review. Pulm Med. 2012;2012:315918. doi: 10.1155/2012/315918. [PubMed: 22900168]. [PubMed Central: PMC3414065].
  • 11. Santillan AA, Camargo CJ, Colditz GA. A meta-analysis of asthma and risk of lung cancer (United States). Cancer Causes Control. 2003;14(4):327-34. [PubMed: 12846363].
  • 12. Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc. 2006;3(6):535-7. doi: 10.1513/pats.200603-089MS. [PubMed: 16921139].
  • 13. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: A systematic review and meta-analysis. PLoS One. 2011;6(3). e17479. doi: 10.1371/journal.pone.0017479. [PubMed: 21483846]. [PubMed Central: PMC3069026].
  • 14. Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer. 2010;67(3):361-5. doi: 10.1016/j.lungcan.2009.05.001. [PubMed: 19487045].
  • 15. Suzuki Y, Suda T, Asada K, Miwa S, Suzuki M, Fujie M, et al. Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis. Clin Vaccine Immunol. 2012;19(3):436-42. doi: 10.1128/CVI.05402-11. [PubMed: 22219312]. [PubMed Central: PMC3294601].
  • 16. Ashizawa K, Matsuyama N, Okimoto T, Hayashi H, Takahashi T, Oka T, et al. Coexistence of lung cancer and tuberculoma in the same lesion: Demonstration by high resolution and contrast-enhanced dynamic CT. Br J Radiol. 2004;77(923):959-62. doi: 10.1259/bjr/31864795. [PubMed: 15507424].
  • 17. Christopoulos A, Saif MW, Sarris EG, Syrigos KN. Epidemiology of active tuberculosis in lung cancer patients: A systematic review. Clin Respir J. 2014;8(4):375-81. doi: 10.1111/crj.12094. [PubMed: 24345074].
  • 18. Tavakoli A. Incidence and prevalence of tuberculosis in Iran and neighboring countries. Zahedan J Res Med Sci. 2017;19(7). e9238. doi: 10.5812/zjrms.9238.
  • 19. World Health Organization. Global tuberculosis report 2017. World Health Organization; 2017.
  • 20. World Health Organization. Tuberculosis profile of Iran (Islamic Republic of) 2016. World Health Organization; 2016.
  • 21. World Health Organization. Treatment success rate for new TB cases: 2015. World Health Organization; 2015.
  • 22. Ramanakumar AV, Parent ME, Menzies D, Siemiatycki J. Risk of lung cancer following nonmalignant respiratory conditions: Evidence from two case-control studies in Montreal, Canada. Lung Cancer. 2006;53(1):5-12. doi: 10.1016/j.lungcan.2006.04.007. [PubMed: 16733074].
  • 23. Littman AJ, Thornquist MD, White E, Jackson LA, Goodman GE, Vaughan TL. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control. 2004;15(8):819-27. doi: 10.1023/B:CACO.0000043432.71626.45. [PubMed: 15456995].
  • 24. Galeone C, Pelucchi C, La Vecchia C, Negri E, Bosetti C, Hu J. Indoor air pollution from solid fuel use, chronic lung diseases and lung cancer in Harbin, Northeast China. Eur J Cancer Prev. 2008;17(5):473-8. doi: 10.1097/CEJ.0b013e328305a0b9. [PubMed: 18714191].
  • 25. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006;42(11):1592-5. doi: 10.1086/503917. [PubMed: 16652317].
  • 26. Hashem Asnaashari AM, Sadrizadeh A, Ahmadi H, Meshkat M, Gholoobi A, Rezai Talab F, et al. The study of Mycobacterium tuberculosis in Iranian patients with lung cancer. Jundishapur J Microbiol. 2013;6(3):237-41. doi: 10.5812/jjm.4993.
  • 27. Suzuki Y, Imokawa S, Sato J, Uto T, Suda T. Cumulative incidence of tuberculosis in lung cancer patients in Japan: A 6-year observational study. Respir Investig. 2016;54(3):179-83. doi: 10.1016/j.resinv.2015.11.001. [PubMed: 27108013].
  • 28. Nisanth PS, Lata N, Gotwal V, Mahajan S. Coexistence of Pulmonary tuberculosis and lung cancer. J Adv Int Med. 2017;6(1):11-3. doi: 10.3126/jaim.v6i1.18313.
  • 29. Florea AM, Busselberg D. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3(1):1351-71. doi: 10.3390/cancers3011351. [PubMed: 24212665]. [PubMed Central: PMC3756417].
  • 30. Amjadi M, Mohammadi Khoshraj J, Majidi MR, Baradaran B, de la Guardia M. Evaluation of Flavonoid Derivative and Doxorubicin Effects in Lung Cancer Cells (A549) Using Differential Pulse Voltammetry Method. Adv Pharm Bull. 2018;8(4):637-42. doi: 10.15171/apb.2018.072. [PubMed: 30607336]. [PubMed Central: PMC6311643].
  • 31. Handayani S, Susidarti RA, Jenie RI, Meiyanto E. Two Active Compounds from Caesalpinia sappan L. in Combination with Cisplatin Synergistically Induce Apoptosis and Cell Cycle Arrest on WiDr Cells. Adv Pharm Bull. 2017;7(3):375-80. doi: 10.15171/apb.2017.045. [PubMed: 29071219]. [PubMed Central: PMC5651058].
  • 32. Jafari H, Gharemohammadlou R, Fakhrjou A, Ebrahimi A, Nejati-Koshki K, Nadri M, et al. Genotyping of Human Papillomavirus and TP53 Mutaions at Exons 5 to 7 in Lung Cancer Patients from Iran. Bioimpacts. 2013;3(3):135-40. doi: 10.5681/bi.2013.018. [PubMed: 24163806]. [PubMed Central: PMC3786796].
  • 33. Jouyban A, Djozan D, Mohammadandashti P, Alizadeh-Nabil A, Ghorbanpour H, Khoubnasabjafari M, et al. Co-liquefaction with acetone and GC analysis of volatile compounds in exhaled breath as lung cancer biomarkers. Bioimpacts. 2017;7(2):99-108. doi: 10.15171/bi.2017.13. [PubMed: 28752074]. [PubMed Central: PMC5524991].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments